Workflow
Dividend and Share Repurchase
icon
Search documents
Xenia Hotels & Resorts Declares Dividend for Second Quarter 2025 and Announces Board Approval for a $100 Million Increase in Share Repurchase Program
Prnewswire· 2025-05-14 10:30
Core Points - Xenia Hotels & Resorts, Inc. announced a cash dividend of $0.14 per share for Q2 2025, payable on July 15, 2025, to shareholders of record as of June 30, 2025 [1] - The Board of Directors also authorized a share repurchase program of up to $100 million, with approximately $180 million remaining under total repurchase authorization as of May 13, 2025 [2] - Xenia is a self-advised and self-administered REIT focused on luxury and upper upscale hotels, owning 30 properties with a total of 8,868 rooms across 14 states [3]
BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM
Prnewswire· 2025-05-07 10:30
Core Points - Bio-Techne Corporation announced a quarterly dividend of $0.08 per share for the quarter ended March 31, 2025, payable on May 30, 2025, to shareholders of record on May 19, 2025 [1] - The company has approved a new share repurchase program authorizing the repurchase of up to $500 million of common stock, starting May 8, 2025, replacing the previous program [2] - Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people globally [3] Dividend Information - The quarterly dividend is set at $0.08 per share for the quarter ended March 31, 2025 [1] - The dividend payment date is May 30, 2025, with a record date of May 19, 2025 [1] Share Repurchase Program - The new share repurchase program allows for the repurchase of up to $500 million of common stock [2] - The program's execution will depend on share price, economic conditions, and regulatory requirements [2] - The company retains the right to suspend, amend, or discontinue the program at any time [2] Company Overview - Bio-Techne is a global life sciences company providing tools and bioactive reagents for research and clinical diagnostics [3] - The company's products support scientific investigations into biological processes and disease progression, aiding drug discovery and clinical testing [3] - Bio-Techne has a diverse portfolio with thousands of products [3]